Cheapest GLP-1 Options Without Insurance [2026]

Last updated: May 2026

Quick Answer:

Lilly Direct self-pay vials list Zepbound (tirzepatide) at $349/month for the 2.5 mg starter dose and $499/month for the 5 mg, 7.5 mg, and 10 mg vials — the cheapest cash-pay path to brand-name tirzepatide in 2026.
Compounded semaglutide from established telehealth platforms runs $129–$299/month, but the FDA officially ended the Wegovy/Ozempic shortage in February 2025 — narrowing the legal lane for 503B mass-compounding after April 22, 2025 enforcement and tightening it further through 2026.
The TrumpRx portal (launched February 6, 2026) offers GLP-1 injectables at $350/month and GLP-1 pills at $149/month under federal agreements signed November 6, 2025 with Novo Nordisk and Eli Lilly.
GoodRx coupons currently show Zepbound vials starting around $995–$1,090/month at retail pharmacies, while the Eli Lilly direct self-pay portal undercuts that by roughly $500/month for the same dose (GoodRx — Zepbound, 2026).
Brand-name retail without any discount remains brutal: Ozempic $1,363, Wegovy $1,637, Mounjaro $1,327, Zepbound $1,059 — but in 2026 nobody who knows the playbook should be paying those numbers.
This page is informational only. Pricing changes monthly, and any prescription decision should run through a licensed clinician — not a Google search.

What cash-pay patients report on Reddit (r/Zepbound, r/Mounjaro, r/Ozempic, 2025)

"I have Aetna and CVS Caremark, so I am losing Zepbound coverage July 1 and will (again) be paying out of pocket. The cheapest price is thru Eli Lilly's cash pay option, Lilly Direct. The treatment initiation dose (2.5 mg) is $349, and the 5 - 10 mg doses are $499 per month for single-use vials." — u/aslguy on r/Zepbound, 2025-05

"Have your doctor prescribe Wegovy and use Novo Nordisk's pharmacy, Novo Care. The cost will be $499 a month. Alternatively you can use the Wegovy Savings Card at any pharmacy for the $499 price. I am a cash pay Ozempic patient and I can't find a price better than about $915 with the SingleCare coupon." — u/PurplestPanda on r/Ozempic, 2025-04

"The vials don't go through insurance at all. LillyDirect Self-Pay vials = nothing goes through insurance. For people who do not have coverage. $349-$499 a month depending on dose. Goes up to 10mg only." — u/Mobile-Actuary-5283 on r/Zepbound, 2025-05

Affiliate disclosure: This article contains affiliate links. We may earn a commission if you make a purchase through our links, at no extra cost to you.

GLP-1 medications transformed weight loss and Type 2 diabetes management between 2023 and 2025. The sticker shock kept millions of Americans from accessing them. At full retail in 2026, a single month of Ozempic still runs $1,363, Wegovy $1,637, Mounjaro $1,327, and Zepbound $1,059 (GoodRx 2026 pricing index).

2026 brought genuine price relief. Eli Lilly's direct self-pay vial program for Zepbound now lists $349 for the 2.5 mg starter dose and $499 for 5 mg, 7.5 mg, and 10 mg vials through LillyDirect.com, the TrumpRx federal portal opened in February 2026 with $149/month pills and $350/month injectables, and Novo Nordisk's NovoCare self-pay program offers Wegovy at $499/month with the savings card. The compounded semaglutide market has narrowed substantially since the FDA officially declared the Ozempic/Wegovy shortage resolved in February 2025 — but legitimate 503A and grandfathered 503B pathways still exist for select patients.

This guide walks through every legitimate option, the real out-of-pocket cost, and the eligibility rules. Pricing is current as of April–May 2026 and is subject to change. Talk to a licensed clinician before starting, switching, or stopping any GLP-1.

The GLP-1 Price Landscape in 2026: What Everything Actually Costs

Before any savings strategy, here is the baseline. These are the full-retail, no-coupon, no-insurance prices at major US retail pharmacies as of April 2026:

Medication	Manufacturer	Type	Monthly Retail Price	FDA Approved For
Ozempic (semaglutide)	Novo Nordisk	Injection	$1,363	Type 2 diabetes
Wegovy (semaglutide)	Novo Nordisk	Injection	$1,637	Weight loss
Wegovy Pill	Novo Nordisk	Oral	$1,200	Weight loss
Mounjaro (tirzepatide)	Eli Lilly	Injection	$1,327	Type 2 diabetes
Zepbound (tirzepatide)	Eli Lilly	Injection	$1,059	Weight loss
Rybelsus (semaglutide)	Novo Nordisk	Oral	$935	Type 2 diabetes
Saxenda (liraglutide)	Novo Nordisk	Injection	$1,430	Weight loss

Those are the numbers almost nobody should be paying in 2026. The rest of this guide walks through every option, ranked from cheapest to most expensive — with the actual eligibility rules and what to verify before signing up.

Option 1: Lilly Direct Self-Pay Vials — $349–$499/Month for Brand-Name Zepbound

The single highest-leverage cash-pay option in 2026 is Eli Lilly's direct-to-consumer Zepbound vial program. Lilly's own pricing page lists the 2.5 mg starter vial at $349/month and the 5 mg, 7.5 mg, and 10 mg single-dose vials at $499/month for patients enrolled in the Self Pay Journey Program (LillyDirect Zepbound self-pay terms).

Two things make this program meaningfully different from a coupon:

It is brand-name tirzepatide direct from the manufacturer. Same molecule, same potency, same FDA approval as the auto-injector pen — just delivered in a single-dose vial that the patient draws with a syringe.
The price is fixed and published, not negotiated coupon-by-coupon at the pharmacy counter.

The 12.5 mg and 15 mg vials are also available through the Self Pay Journey Program, priced at $849 and $1,049 respectively when refilled within 45 days of the previous delivery — the discount lapses if the refill window is missed. Pricing details, eligibility, and the refill-cadence rules are on the LillyDirect program page.

A practical caveat reported by long-time Zepbound patients: vials require manual draw with a syringe rather than the auto-injector pen, which is a meaningful workflow shift for anyone who started on the pens. The cost savings are large enough that most cash-pay patients accept the trade — but it is worth knowing before signing up.

For a side-by-side of brand-name versus compounded tirzepatide, see Option 1B below.

Option 1A: Compounded Semaglutide — $129–$299/Month, With Important 2026 Caveats

Compounded semaglutide was the cheapest GLP-1 path during the 2023–2024 Ozempic/Wegovy shortage. In 2026, the legal lane is narrower — but still exists for many patients.

How the FDA Shortage Resolution Changed Things

The FDA officially declared the semaglutide shortage resolved on February 21, 2025, and large-scale 503B mass-compounding of semaglutide ended April 22, 2025 (FDA — concerns with unapproved GLP-1 drugs). That changed the legal landscape:

503A pharmacies can still legally compound semaglutide for individual patients on patient-specific prescriptions when a documented medical need exists (allergy to an inactive ingredient, dose not commercially available, etc.).
503B outsourcing facilities can no longer mass-produce semaglutide for telehealth-channel distribution the way they did in 2023–2024.

Several large telehealth platforms have either narrowed their compounded semaglutide offerings, shifted toward documented medical-need workflows, or pivoted toward compounded tirzepatide (which has different shortage status). Always verify a pharmacy's accreditation status, 503A versus 503B designation, and the specific medical-need documentation before paying.

Actual Compounded Pricing Reported (April–May 2026)

Provider	Monthly Cost	Pharmacy Type
Hims (first-month promo)	$129/month	telehealth-network
Peak Wellness	$149/month	503A
Ro	$199/month	telehealth-network
MEDVi	$197/month	503A
Henry Meds	$249/month	503A
Found	$299/month	telehealth-network

Prices are subject to change and are listed for context only. This is not a recommendation to compound — patients should weigh compounded semaglutide against brand-name options like Lilly Direct vials (different molecule, different FDA approval pathway) with a licensed clinician who can review their specific medical history.

What to Watch Out For

Look for these before paying any compounding pharmacy:

PCAB accreditation (Pharmacy Compounding Accreditation Board) — the established quality standard
503A versus 503B designation clearly disclosed
Certificate of Analysis for each batch showing potency and sterility testing
USP 797/795 compliance for sterile compounding standards

A 2024 FDA investigation cited in the agency's enforcement letters found that several tested compounded semaglutide samples failed potency testing, delivering between 60% and 140% of the labeled dose. Enforcement actions through 2025 and into 2026 have closed many of the worst offenders, but the spec sheet still varies pharmacy by pharmacy.

For a deeper dive into safety considerations, see our compounded semaglutide safety guide.

Option 1B: Compounded Tirzepatide ($299-$399/Month)

A significant development in 2026 is the growing availability of compounded tirzepatide, giving patients who want the dual GIP/GLP-1 mechanism a more affordable path than brand-name Mounjaro or Zepbound.

Why This Matters

Tirzepatide has shown stronger weight loss results than semaglutide in head-to-head clinical trials, but until recently the only affordable compounded option was semaglutide. That gap has closed. Several telehealth platforms now offer compounded tirzepatide at prices significantly below the $1,059-$1,327 retail cost of brand-name versions.

Current Compounded Tirzepatide Pricing (April 2026)

Provider	Monthly Cost	Includes
SynergyRx	$299/month	Medication + consultation
GobyMeds	$319/month	3-month starter bundle
Peak Wellness	$347/month	Medication + provider visits
Henry Meds	$399/month	Medication + monthly check-ins

Key Considerations

Compounded tirzepatide carries the same quality concerns as compounded semaglutide -- verify the pharmacy's 503B registration and PCAB accreditation before ordering. The market for compounded tirzepatide is less mature than semaglutide, so fewer providers offer it and pricing has not dropped as aggressively. Still, paying $299-$399/month versus $1,059-$1,327/month represents savings of 70-77%, making it a viable option for patients who specifically want tirzepatide.

Option 2: TrumpRx Portal + Manufacturer Deals ($149-$350/Month)

The TrumpRx program, launched February 6, 2026, represents the biggest federal intervention in GLP-1 pricing to date.

What TrumpRx Actually Does

TrumpRx (trumprx.gov) is not a pharmacy. It is a government portal that connects patients to manufacturer discount programs and partner pharmacies. Think of it as a federally backed coupon aggregator specifically designed for high-cost medications.

Current TrumpRx Pricing for GLP-1s

Medication	TrumpRx Price	Savings vs. Retail
GLP-1 injectables (starting doses)	$350/month	73-79% off
GLP-1 pills (starting doses)	$149/month	84-88% off
Projected price by 2028	$245/month (injectables)	82-85% off

The Backstory

On November 6, 2025, the Trump administration reached agreements with both Novo Nordisk and Eli Lilly to substantially reduce GLP-1 prices. These deals cover Wegovy, Ozempic, Mounjaro, and Zepbound for uninsured patients and certain Medicare recipients.

Starting mid-2026, Medicare will cover injectable weight-loss medications for eligible individuals with severe obesity (BMI 40+ or BMI 35+ with comorbidities) at a maximum $50/month copay. This is a historic shift -- Medicare has never covered weight loss drugs before.

How to Use TrumpRx

Visit trumprx.gov
Enter your medication name
The portal shows available manufacturer discounts and participating pharmacies
You get a discount code or coupon to present at checkout
No income verification required

TrumpRx Limitations to Know

The main limitation is that TrumpRx pricing is not always the cheapest option. For semaglutide specifically, compounded versions from telehealth platforms often beat TrumpRx prices by $100-$200 per month. But for tirzepatide (Mounjaro/Zepbound), where compounded alternatives are still more expensive, TrumpRx may offer competitive value.

Also worth noting: patients with government-funded insurance, including Medicare and Medicaid, are typically excluded from manufacturer savings cards and discount programs linked through the portal. The TrumpRx deals are primarily designed for the uninsured and commercially insured whose plans do not cover GLP-1s.

TrumpRx Adoption So Far

The portal has seen significant uptake since its February launch, though exact usage numbers have not been publicly reported. Anecdotally, the biggest complaint from users is that not all local pharmacies participate in the program, which can mean driving further to fill a prescription or switching to mail-order fulfillment. If you are in a rural area, confirm pharmacy availability in your ZIP code before relying on TrumpRx as your primary savings strategy.

Option 3: GoodRx Coupons and Manufacturer Intro Offers ($149-$499/Month)

GoodRx remains one of the most accessible savings tools for brand-name GLP-1 medications, and both GoodRx and the manufacturers themselves have active introductory pricing specifically for GLP-1s in 2026.

Brand-Name GLP-1 Introductory Pricing (April 2026)

Medication	Introductory Price	Offer Valid Through	Ongoing Price	Retail Price
Ozempic 0.25-1mg	$199/month (first 2 fills)	June 30, 2026	$349/month	$1,363
Ozempic 2mg	$199/month (first 2 fills)	June 30, 2026	$499/month	$1,363
Wegovy (injection)	$199/month (first 2 fills)	June 30, 2026	$349/month	$1,637
Wegovy (pill, 1.5-4mg)	$149/month	August 31, 2026	$149/month	$1,200
Wegovy (pill, 9-25mg)	$149/month	August 31, 2026	$299/month	$1,200
Zepbound	$449/month (self-pay)	December 31, 2026	$449/month	$1,059
Mounjaro	N/A	N/A	~$1,097	$1,327

The big update here: Novo Nordisk has extended their introductory offers through mid-2026, and Eli Lilly is now offering eligible self-pay patients a 1-month supply of Zepbound for $449 through the end of 2026. That Zepbound pricing is not as competitive as semaglutide options, but it matters for patients who specifically need tirzepatide.

GoodRx also offers a $39/month telemedicine subscription for weight loss consultations, which includes the prescription but not the medication itself. This can be a cost-effective way to get a prescription if you already know where you want to fill it.

The GoodRx Strategy

The introductory pricing makes GoodRx excellent for the first two months, but the jump to $349-$499 for ongoing fills makes it less competitive long-term compared to compounded options. Our recommended approach: use GoodRx introductory pricing while you evaluate telehealth compounding programs, then switch to whichever option delivers the best ongoing value.

One thing worth watching: GoodRx has been expanding its direct-to-consumer GLP-1 offerings throughout 2026, and there are signs they may introduce a more competitive ongoing pricing tier before year-end to compete with the flood of telehealth compounding platforms eating into their market share.

For a complete breakdown of costs across all GLP-1 medications, check our GLP-1 medication cost guide and our how much does GLP-1 medications cost in 2026 complete pricing guide.

Option 4: Manufacturer Savings Programs ($0-$500/Month)

Both Novo Nordisk and Eli Lilly operate patient assistance programs that can dramatically reduce or even eliminate costs for qualifying patients. For a side-by-side ranking of every active savings card and discount in 2026, see our GLP-1 savings programs and discounts ranked guide.

Novo Nordisk Programs

Ozempic Savings Card: Commercially insured patients may pay as little as $25 for a 1-month or 3-month supply. Does NOT apply to uninsured patients.

NovoCare Patient Assistance Program (PAP): For uninsured patients earning under 400% of the Federal Poverty Level (~$58,320 for a single person in 2026), Novo Nordisk provides Ozempic, Wegovy, Rybelsus, and Saxenda at no cost for up to one year. This is the best-kept secret in GLP-1 affordability. The income threshold is higher than most people expect, and the application process has been streamlined for 2026 with an online portal that gives preliminary eligibility decisions within minutes.

NovoCare Pharmacy: Novo Nordisk has also launched NovoCare Pharmacy, a direct-to-patient delivery service that simplifies the fulfillment process for patients using their savings programs. If you qualify for a NovoCare discount, you can now get your medication shipped directly to your door through their own pharmacy channel. This removes the friction of finding a participating retail pharmacy and reduces the chance of a pharmacist rejecting your discount code at the counter.

Eli Lilly Programs

Zepbound Savings Card: Eligible patients can pay as low as $25/month. Available for commercially insured patients whose plans do not cover Zepbound.

Zepbound Self-Pay Program: Through December 31, 2026, Lilly offers a 1-month supply of Zepbound for $449 for eligible self-pay patients without insurance coverage. This is separate from the savings card and targets the uninsured directly.

Lilly Cares Foundation: Provides free medications for patients who are uninsured, underinsured, or cannot afford their medications. Income limits apply but are more generous than most people expect. Applications can be submitted online or by phone, and approval typically takes 2-4 weeks.

Who Actually Qualifies

The income thresholds for manufacturer PAPs are higher than most people realize. If you are uninsured and earn under $60,000/year as a single filer, you should apply before exploring any paid option. The application takes about 15 minutes and typically requires proof of income (tax return or pay stubs) and a prescription from your provider. For couples filing jointly, the income threshold is roughly $79,000 in 2026. Do not assume you make too much -- apply first, pay later only if denied.

Walgreens Weight Management Program

Walgreens has entered the GLP-1 space with a weight management program that bundles telehealth consultations with medication access. Patients can get GLP-1 prescriptions through Walgreens' virtual healthcare platform, which may offer competitive pricing for those who prefer a brick-and-mortar pharmacy backing their prescription. The program includes ongoing pharmacist check-ins and weight tracking, positioning it as a full-service option rather than just a dispensing channel. Check walgreens.com for current pricing and availability in your area.

Option 5: International Pharmacies ($200-$400/Month)

Some Americans order GLP-1 medications from Canadian or international pharmacies, where the same brand-name drugs cost a fraction of US prices.

Approximate International Pricing

Medication	US Retail	Canadian Pharmacy	Savings
Ozempic 1mg	$1,363/month	$300-$400/month	70-78%
Wegovy	$1,637/month	$350-$450/month	72-79%
Rybelsus 14mg	$935/month	$200-$300/month	68-79%

Legal Considerations

The FDA technically prohibits importing prescription medications for personal use, but enforcement has historically been minimal for small quantities (90-day supply or less) ordered by individuals. The FDA's personal importation policy generally allows looking the other way when patients import medications for personal use in quantities that do not exceed a 3-month supply, provided no commercial distribution is involved.

Risks include: receiving counterfeit products, inconsistent quality control, and potential legal exposure. If you choose this route, verify the pharmacy through the Canadian International Pharmacy Association (CIPA) or PharmacyChecker.

Important Context for 2026

International pharmacy pricing has become somewhat less attractive relative to domestic options compared to a year ago. With compounded semaglutide available domestically for $99-$199/month and the TrumpRx portal offering brand-name discounts, the value proposition of importing from Canada has narrowed. International pharmacies still make sense if you specifically want brand-name Novo Nordisk or Eli Lilly products at a discount but do not qualify for domestic manufacturer assistance programs.

Option 6: Direct-Pay Telehealth Programs ($199-$399/Month)

A growing category in 2026 is the direct-pay telehealth model, where platforms handle everything from the medical evaluation to medication delivery in a single subscription. These differ from pure compounding pharmacy plays in that they often include more comprehensive clinical oversight.

How Direct-Pay Programs Work

You sign up, complete a health questionnaire, have a video or async consultation with a licensed provider, and if approved, receive your medication by mail. The subscription typically covers the provider relationship, prescription, medication, and shipping. No insurance filing, no pharmacy visits, no surprise bills.

Notable Direct-Pay Programs (April 2026)

Provider	Monthly Cost	What Is Included	Medication Type
Hims/Hers	$129-$209/month	Provider, Rx, medication, delivery	Compounded semaglutide
Ro	$199/month	Provider, Rx, medication, support	Compounded semaglutide
Found	$299/month	Provider, Rx, medication, coaching, app	Compounded semaglutide
Noom GLP-1	$299-$349/month	Provider, Rx, medication, behavioral coaching	Compounded semaglutide

Why This Category Is Growing

The appeal is simplicity. No navigating insurance denials, no prior authorizations, no pharmacy callbacks. You pay one price and get everything. For busy professionals who value their time, the modest premium over a bare-bones compounding option (say, $199/month vs. $99/month) may be worth the convenience and clinical support.

The downside: you are still getting compounded medication in most cases, not brand-name FDA-approved products. If you specifically want Ozempic or Wegovy, you will need to go through a traditional pharmacy with GoodRx coupons, TrumpRx, or a manufacturer savings program.

Complete Cost Comparison: All Options Side by Side

Here is every legitimate pathway ranked by monthly out-of-pocket cost, updated for April 2026:

Pathway	Monthly Cost	Best For	Key Limitation
Manufacturer PAP	$0	Low-income uninsured	Income limits apply
Medicare (mid-2026)	$50 copay	Medicare recipients with BMI 35+	Must qualify for Medicare
Compounded semaglutide (cheapest)	$99-$129	Budget-conscious, flexible on brand	Not FDA-approved product
Wegovy pill (intro pricing)	$149	Want FDA-approved oral option	Price may increase after August 2026
Compounded semaglutide (mid-tier)	$149-$249	Want included monitoring	Varies by pharmacy quality
GoodRx (introductory)	$199	First 2 months of brand-name injectable	Jumps to $349+ after; offer ends June 2026
International pharmacy	$200-$400	Want brand-name, accept legal gray area	Import risks
Compounded semaglutide (premium)	$249-$299	Want coaching + medication	Could get same drug cheaper
Compounded tirzepatide	$299-$399	Want dual GIP/GLP-1 mechanism	Fewer providers, less price competition
TrumpRx (injectables)	$350	Want brand-name domestic	Not always cheapest
GoodRx (ongoing)	$349-$499	Need brand-name ongoing	Expensive long-term
Zepbound self-pay	$449	Need tirzepatide specifically	Offer valid through Dec 2026

Which Option Should You Choose? A Decision Framework

Choosing the right cost-saving pathway depends on your specific situation. Here is a practical decision tree:

If you are uninsured and earn under $60,000/year:

Start with manufacturer Patient Assistance Programs (PAPs). You may qualify for free medication. Apply to NovoCare or Lilly Cares first. This step costs you nothing but 15 minutes of paperwork, and the potential savings are enormous. The 2026 application process is faster than previous years -- NovoCare now offers a streamlined online portal that gives preliminary eligibility decisions in minutes rather than weeks.

If you are uninsured and earn over $60,000/year:

Compounded semaglutide from an accredited telehealth platform ($129-$249/month) delivers the best value. Verify the pharmacy is PCAB-accredited or a 503B outsourcing facility. Look for bundled programs that include the provider visit, prescription, medication, and delivery in one price so you do not get hit with hidden fees. Pay close attention to the SynergyRx findings about hidden costs -- ask every provider upfront whether shipping, consultation, and dose-escalation fees are included in the quoted price.

If you want brand-name medication:

Use GoodRx or Novo Nordisk introductory pricing ($199/month for 2 months, valid through June 30, 2026) while applying to the TrumpRx portal for ongoing savings. Check whether your state Medicaid program covers GLP-1s, as several states added coverage in 2025-2026.

If you want an oral option:

The Wegovy pill at $149/month (through August 31, 2026 via Novo Nordisk's self-pay offer) is the cheapest FDA-approved oral GLP-1. This is a strong option for people who dislike injections and want the confidence of an FDA-approved product. MEDVi also offers compounded oral semaglutide at competitive pricing for patients who want an oral option but prefer the lower cost of a compounded formulation.

If you are on Medicare:

Wait for the mid-2026 coverage expansion if you can. Once active, you will pay a maximum $50/month copay for injectable GLP-1s if you meet obesity criteria. Be aware that manufacturer savings cards and discount programs typically exclude Medicare patients. If you cannot wait, compounded semaglutide platforms do not require insurance information and are available to anyone regardless of Medicare status.

If you have diabetes (type 2):

You may have additional insurance pathways since GLP-1s for diabetes have broader coverage than GLP-1s for weight loss. Check your plan's formulary -- many commercial plans cover Ozempic or Mounjaro for diabetes with reasonable copays even if they do not cover them for weight loss.

If you specifically need tirzepatide (Mounjaro/Zepbound):

Your options have expanded since early 2026. Our Zepbound complete guide covers the drug's full clinical profile alongside cost-saving paths. Compounded tirzepatide is now available from select telehealth platforms at $299-$399/month, a meaningful savings over brand-name pricing of $1,059-$1,327. Lilly's self-pay program at $449/month (through December 2026) remains the most straightforward path for brand-name Zepbound. TrumpRx may also offer better pricing depending on your location. The compounded tirzepatide market is still maturing, so expect prices to continue declining through the rest of 2026 as more providers enter the space.

If you want the strongest weight loss results:

Tirzepatide (Mounjaro/Zepbound or compounded tirzepatide) has shown superior weight loss in clinical trials compared to semaglutide, with patients losing an average of 20-25% of body weight versus 15-17% for semaglutide. If maximizing weight loss is your priority and budget allows, compounded tirzepatide at $299-$399/month may deliver better value per pound lost than cheaper semaglutide options.

For help choosing the right GLP-1 medication for your specific goals, see our guide to choosing between GLP-1s for weight loss vs diabetes.

How to Verify a Compounding Pharmacy Is Legitimate

Because compounded semaglutide is the cheapest option and also carries the most quality variability, verification matters. Here is a step-by-step process:

Check 503B registration: Search the FDA's list of registered outsourcing facilities at FDA.gov. 503B facilities are inspected by the FDA. As of April 2026, there are over 80 registered 503B outsourcing facilities in the US, but not all compound GLP-1 medications.
Look for PCAB accreditation: Visit the Accreditation Commission for Health Care (ACHC) website to verify PCAB status. PCAB-accredited pharmacies undergo rigorous inspections and must meet standards that go beyond basic state requirements.
Request a Certificate of Analysis (COA): Any legitimate pharmacy should provide a COA showing potency, sterility, and endotoxin testing for each batch. If a pharmacy refuses or says they do not have one, that is a dealbreaker. Walk away.
Verify USP compliance: Ask whether the pharmacy follows USP 797 (sterile compounding) and USP 795 (non-sterile compounding) standards.
Check state licensing: Verify the pharmacy is licensed in your state through your state Board of Pharmacy website.
Ask about dose consistency: A reputable pharmacy should be able to confirm that the price stays the same across dose levels. If a provider charges more as your dose increases, that is a yellow flag -- it may indicate they are reselling rather than compounding.
Look for third-party testing: Some of the more transparent compounding pharmacies now publish third-party potency testing results on their websites. This is a strong positive signal and becoming an industry best practice in 2026.

The Price Trajectory: Where GLP-1 Costs Are Heading

Several factors suggest GLP-1 prices will continue dropping through 2026 and beyond:

Generic semaglutide: The earliest generic versions could arrive by late 2026 or 2027 as certain patents expire, potentially pushing prices below $100/month. For the latest on generic timelines, see our generic semaglutide coverage.
Oral formulations gaining ground: The Wegovy pill, already on market at $149/month self-pay for starting doses, costs less to manufacture than injectables and could drive prices down further as production scales through the rest of 2026.
Next-generation drugs: Competitors like survodutide and orforglipron could increase market competition significantly. Orforglipron in particular is an oral GLP-1 that does not require refrigeration, which would dramatically simplify distribution and lower costs. Our next-gen GLP-1 pipeline article tracks what is coming.
TrumpRx price targets: The administration projects injectable prices dropping to $245/month by 2028 through continued manufacturer negotiations.
Employer coverage expansion: A 2025 Mercer survey found 44% of large employers now cover GLP-1s for weight loss, up from 27% in 2024. That trend is continuing into 2026 as employers recognize the downstream healthcare cost savings. Some analysts project employer coverage will exceed 55% by the end of 2026.
Telehealth competition intensifying: The number of telehealth platforms offering compounded semaglutide has roughly doubled since early 2025. More competition means lower prices. Platforms are now competing on bundled services (coaching, monitoring, delivery) rather than just medication cost. The entry of compounded tirzepatide options has further expanded patient choice and put downward pressure on pricing across the board.
Retail pharmacy entry: Major retailers like Walgreens are now offering integrated weight management programs with GLP-1 access, adding another competitive pressure point to the market.
Insurance policy shifts: Several major insurers, including UnitedHealthcare and Cigna, expanded GLP-1 coverage for weight loss in their 2026 plan years. While this does not directly affect uninsured patients, it increases overall demand and manufacturer production volumes, which can indirectly lower costs for self-pay patients through economies of scale.

Frequently Asked Questions

What is the absolute cheapest GLP-1 medication without insurance in 2026?

Compounded semaglutide from budget telehealth platforms starts at $99-$129/month, making it the cheapest option for patients who do not qualify for free medication through manufacturer programs. However, if you qualify for a manufacturer Patient Assistance Program based on income (under approximately $58,320/year for a single person), you can get brand-name GLP-1s for free. The cheapest FDA-approved brand-name option is the Wegovy pill at $149/month via Novo Nordisk's self-pay offer, valid through August 31, 2026. For patients who specifically want tirzepatide rather than semaglutide, compounded tirzepatide starts at approximately $299/month.

Is compounded semaglutide the same as Ozempic?

Compounded semaglutide contains the same active ingredient (semaglutide) as Ozempic and Wegovy, but it is not an identical product. Compounded versions are mixed by pharmacies rather than manufactured by Novo Nordisk, which means they lack FDA approval as a finished product. Quality can vary between pharmacies, which is why choosing a PCAB-accredited or 503B-registered pharmacy is critical. The active molecule is the same, but differences in formulation (inactive ingredients, preservatives, concentration) mean the injection experience and absorption profile may differ slightly from brand-name versions.

Will Medicare cover GLP-1 weight loss drugs in 2026?

Yes. Starting mid-2026, Medicare will cover injectable GLP-1 medications including Ozempic, Wegovy, Mounjaro, and Zepbound for eligible individuals with severe obesity (BMI 40+ or BMI 35+ with comorbidities). The maximum copay will be $50/month. This coverage expansion resulted from November 2025 agreements between the Trump administration and both Novo Nordisk and Eli Lilly. This is a historic policy shift -- Medicare has never before covered medications specifically for weight loss, and the change is expected to make GLP-1 therapy accessible to millions of older Americans who were previously priced out.

How does TrumpRx work for GLP-1 savings?

TrumpRx (trumprx.gov) is a government portal that connects patients to manufacturer discount programs and partner pharmacies. It is not a pharmacy itself. You enter your medication, receive discount codes or coupons, and present them at participating pharmacies. Current GLP-1 injectable pricing through TrumpRx is approximately $350/month, with GLP-1 pills starting at $149/month. No income verification is required. The portal launched on February 6, 2026, and has been adding new participating pharmacies on a rolling basis. Check availability in your ZIP code before relying on it as your primary savings pathway.

Are international pharmacies a safe option for buying GLP-1 drugs?

Ordering from verified Canadian pharmacies through organizations like CIPA or PharmacyChecker can provide genuine brand-name GLP-1 medications at 70-80% savings. However, the FDA technically prohibits personal importation, enforcement is minimal for small quantities (90-day supply), and risks include receiving counterfeit products. This option works best as a short-term bridge while exploring domestic alternatives. With compounded semaglutide now available domestically for as little as $99-$129/month, the cost advantage of importing from Canada has narrowed considerably compared to previous years.

How much does Zepbound cost without insurance in 2026?

Eli Lilly is offering eligible self-pay patients a 1-month supply of Zepbound for $449 through December 31, 2026. Without any discount program, Zepbound retails at $1,059/month. The Lilly Cares Foundation may also provide free Zepbound for patients who meet income requirements. A newer option as of 2026 is compounded tirzepatide (the same active ingredient as Zepbound), which is available from select telehealth platforms for $299-$399/month, offering an even lower-cost alternative for patients who specifically want tirzepatide.

Do GLP-1 prices stay the same as my dose increases?

It depends on the pathway. Most compounded semaglutide programs from telehealth providers charge a flat monthly rate regardless of dose -- one of their biggest advantages. Brand-name medications through GoodRx and retail pharmacies may cost more at higher doses (for example, GoodRx ongoing pricing is $349/month for Ozempic 0.25-1mg but $499/month for the 2mg dose). Always confirm dose-based pricing before committing to a program. This is especially important for compounded tirzepatide, where some providers do charge higher prices at maintenance doses.

Can I switch between compounded and brand-name GLP-1 medications?

Yes. Many patients start with brand-name GLP-1s using introductory pricing (like GoodRx's $199/month for the first 2 fills) and then transition to compounded versions for ongoing treatment at a lower cost. The reverse also works -- some patients start with compounded semaglutide to see if they tolerate the medication, then switch to brand-name if they prefer the consistency of an FDA-approved product. Your prescribing provider can help manage the transition, but be aware that doses are not always directly interchangeable between compounded and brand-name formulations, so a brief dose adjustment period may be needed.

What happens to compounded semaglutide if the FDA shortage ends?

This is one of the most important questions for patients relying on compounded GLP-1 medications. Compounding pharmacies are legally allowed to produce copies of brand-name drugs during shortages. If the FDA declares that the semaglutide shortage has officially ended, 503A pharmacies would need to stop producing compounded semaglutide, while 503B outsourcing facilities may have a wind-down period. As of April 2026, semaglutide remains on the FDA shortage list, but this could change. Patients using compounded semaglutide should have a backup plan -- whether that is transitioning to brand-name with manufacturer discounts or exploring compounded tirzepatide as an alternative.

The Bottom Line

Nobody should pay full retail price for GLP-1 medications in 2026. Between compounded semaglutide ($99-$299/month), compounded tirzepatide ($299-$399/month), TrumpRx ($149-$350/month), GoodRx and manufacturer introductory pricing ($149-$199/month), manufacturer PAPs ($0 for qualifying patients), and upcoming Medicare coverage ($50/month copay), the gap between GLP-1 prices and GLP-1 accessibility has never been smaller.

The smartest strategy is to layer these options: apply for manufacturer assistance first, use introductory pricing (GoodRx or Novo Nordisk direct offers, valid through June-August 2026) while waiting, then transition to compounded semaglutide or TrumpRx for ongoing treatment. If you prefer an oral option, the Wegovy pill at $149/month is now a legitimate contender. And if you want tirzepatide's stronger weight loss results without the $1,059+ brand-name price tag, compounded tirzepatide from an accredited pharmacy is a new pathway that did not exist at scale even six months ago.

With GLP-1 prices projected to continue dropping through 2028, generic semaglutide on the horizon, and next-generation oral GLP-1s like orforglipron working through clinical trials, the cost barrier that kept these medications out of reach for millions of Americans is finally breaking down.

For a comprehensive look at all GLP-1 medications and how they compare, see our best GLP-1 medications for weight loss guide. And if you are new to GLP-1 therapy entirely, our beginner's guide covers everything you need to know before starting.